Health and FitnessHealth and Fitness
Tue, April 17, 2012
[ Tue, Apr 17th 2012 ] - Market Wire
Rambler Holdings in Company
Mon, April 16, 2012

Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference


Published on 2012-04-16 13:46:56 - Market Wire
  Print publication without navigation


Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the... -- POINT RICHMOND, Calif., April 16, 2012 /PRNewswire/ --

Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference

[ ]

POINT RICHMOND, Calif., April 16, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: [ TSPT ]), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present at the BioCentury Future Leaders in the Biotech Industry Conference in New York on April 20, 2012 at 8:30 a.m. ET.

(Logo:  [ http://photos.prnewswire.com/prnh/20101102/SF93452LOGO ])

A live audio webcast and replay of this presentation may be accessed at [ http://www.media-server.com/m/p/dnf5o64x ] and on the Transcept Investor webpage at [ www.transcept.com ].

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit  [ www.transcept.com ].

Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Sr. Director, Corporate Communications
(510) 215-3567
[ gmann@transcept.com ]

SOURCE Transcept Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.transcept.com ]